SCHEMBL855072

SCHEMBL855072

CC(N)c1ccccc1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.48
HTR2A P28223 1/20 0.47
TAAR1 Q96RJ0 4/20 0.47
SLC6A2 P23975 2/20 0.47
SIGMAR1 Q99720 2/20 0.47
MAOA P21397 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CYP2A6 P11509 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
SLC18A2 Q05940 1/20 0.44
CALM1 P0DP23 1/20 0.42
BCL2 P10415 1/20 0.41
BCL2L1 Q07817 1/20 0.41
EPHX1 P07099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160889 1.00 CYP2D6 (0.48) CYP2D6HTR2ATAAR1SLC6A2SIGMAR1
SCHEMBL6314764 0.87 CYP2D6 (0.43) CYP2D6TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL23457325 0.87 SMN1; SMN2 (0.37) CYP2D6HTR2ATAAR1SLC6A2SIGMAR1
SCHEMBL6546687 0.83 L3MBTL1 (0.47) HTR2ATAAR1SLC6A2SIGMAR1MAOA
SCHEMBL10599552 0.82 SIGMAR1 (0.52) CYP2D6TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL21471624 0.82 L3MBTL1 (0.46) CYP2D6HTR2ATAAR1SIGMAR1MAOA
Hydrogen Peroxide SCHEMBL29140083 0.82 L3MBTL1 (0.50) HTR2ASLC6A2L3MBTL1CALM1BCL2
SCHEMBL9113255 0.80 L3MBTL1 (0.49) HTR2ATAAR1L3MBTL1CALM1BCL2
SCHEMBL27428238 0.80 L3MBTL1 (0.49) HTR2ATAAR1L3MBTL1CALM1BCL2
SCHEMBL27683376 0.79 HTR2A (0.47) HTR2ATAAR1SLC6A2SIGMAR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807294-B1 PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3 ACRAF (IT) 2026-01-14 EP claimed
EP-3807293-B1 PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS ACRAF (IT) 2026-01-14 EP claimed
US-20230372492-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME MISSISSIPPI STATE UNIVERSITY (US) 2023-11-23 US claimed
EP-4221755-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME Mississippi State University (US) 2023-08-09 EP claimed
WO-2022072425-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME PARK JOO YOUN (US) 2022-04-07 WO claimed
CN-107474208-B A kind of multi-functional benzoxazine composite material and preparation method 四川天策聚材科技有限公司 2019-10-22 CN claimed
CN-110156982-A A kind of liquid liquid homogeneous method using continuous flow micro passage reaction synthesis polyarylether 常州中英新材料有限公司 2019-08-23 CN claimed
CN-110156983-A Liquid-liquid heterogeneous method for synthesizing polyarylether by using continuous flow microchannel reactor 常州中英新材料有限公司 2019-08-23 CN claimed
CN-104628892-B Preparation method and use of 6-benzyl phenylethylamine derivative beta-cyclodextrin bonded SBA-15 南昌大学 2017-02-22 CN claimed
CN-106397273-A Improved preparation method of sacubitril intermediate 四川海思科制药有限公司 2017-02-15 CN claimed
EP-2207776-B9 DRUG ACTIVE IN NEUROPATHIC PAIN ACRAF (IT) 2016-12-21 EP claimed
EP-2207776-B1 DRUG ACTIVE IN NEUROPATHIC PAIN ACRAF (IT) 2016-08-17 EP claimed
CN-104628892-A Preparation method and use of 6-benzyl phenylethylamine derivative beta-cyclodextrin bonded SBA-15 UNIV NANCHANG 2015-05-20 CN claimed
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP claimed
EP-3807294-A1 PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2021-04-21 EP disclosed
EP-3807293-A1 PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2021-04-21 EP disclosed
WO-2019238686-A1 PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.P.A. (IT) 2019-12-19 WO disclosed
US-20040067981-A1 Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants SANKYO COMPANY, LIMITED (JP) 2004-04-08 US disclosed
EP-1362844-A1 BENZYLAMINE ANALOGUE Sankyo Company, Limited (JP) 2003-11-19 EP disclosed
EP-0429149-A1 Tricyclic pteridinones and a process for their preparation BERLEX LABORATORIES, INC. (US) 1991-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372492-A1 DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME GFPT1, PHPT1, SLC2A1 CYP2D6 255/4885HTR2A 2919/4885TAAR1 4381/4885
US-20040067981-A1 Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants ACHE, BACE1, CHRNA6 CYP2D6 613/4885HTR2A 97/4885TAAR1 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.